ASH25 Day 1: Don’t Miss The Highlights
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.
It aims to bring together hematology professionals from across the globe.
Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.
Find the highlights from Day 1
”API-CAT Post-hoc of Isabelle Mahe at ASH25
Predictors of clinically relevant bleeding during extended apixaban for cancer-associated VTE:
- Anemia/Thrombocytopenia high risk (HR 1.93)
- Age ≥75 ↑ (1.51)
- Index PE – high (1.47)
- Male sex – high (1.38)
Findings consistent across cancer types.
”
”ASH25 “decoding DDX41 mutant HR-MDS and AML”
Conclusion:
1. Not every DDX41-mutant HR-MDS/AML responds well to venetoclax plus HMA.
2. no survival difference between pathogenic vs VUS variants.
3. Splicing-factor co-mutations predicted worse outcomes, while allo-HCT trended better.
Highlights need for larger cohorts to refine predictors.
”
”ASH25 Stop today by our poster 2712 “Interim analysis of a non-interventional prospective study to assess the impact on Patient’s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and R/R CLL in routine clinical practice in Spain
”
”Casulo et al: A-HIPI in S1826
– compared with IPS, A-HIPI superior
– Better prognostication: HR 2.4 for pts above median A-HIPI
– Better discrimiation: C-stat 0.627 (vs 0.591)
– Held for both regimens
– best prog 18-40y
Still not a perfect score, but better!
”
”Great presentation by Amer Zeidan of Bexmarilimab- 1st in class Clever-1 Ab- w/ Aza in 1L and R/R HR- MDS w/enrichment for TP53m.
Impressive data both in 1L and R/R MDS.
Privilege to enroll on this study at UNC Lineberger and looking forward to next steps.
”
”Was hopeful reduction in days of AZA (AZA5) with VEN would hold up.
Per VenAza-5S not yet.
cCR 51.1% (*VIALE-A 66.4%)
mOS 9.8mo (*14.7mo)
Gr.3 FN 13% (*30%)
Awaiting the SAL propensity matched analysis but for now we’re stuck with AZA7.
”
”Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at ASH25 – the largest cohort of paired tumor and remission WGS from patients with AML
Read the full article.
”
”Are Ven+Gilt-based regimens safe and effective for FLT3m AML in the real-world setting?
Stop at our poster No 1679: CR+CRp 82%, ORR 95%, mOS 25mo in ND + R/R pts. 40% bridged to alloSCT.
No signals of excessive toxicity or prolonged myelosupression
”
”All-star expert line-up at the Treatment Advances in HR-MDS session at ASH2025 discussing HMA+Ven in frontline HR-MDS and t-MDS.
Unfortunately no improvement in OS when compared with HMA.
Future research likely to identify subgroups that will benefit most from this combination.
”
”Bispecific antibodies as frontline for older adults w/DLBCL at ASH2025
My conclusions:
BiTEs monotherapy ≈ R-miniCHOP
Adding drugs to BiTEs = higher efficacy and AEs
Geriatric assessment and evaluation of anthracycline eligibility are mandatory to apply best approach!
”
More from ASH25 featured in Hemostasis Today.
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines
-
Dec 5, 2025, 03:45Ardeshir Khademi: A Clinical Lesson on Thrombophilia, Silent Infarcts, and Asking the Right Questions